查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951778

高通量篩檢(HTS) 市場分析及至 2035 年預測：按類型、產品類型、服務、技術、組件、應用、最終用戶、流程、部署類型和功能分類

High-Throughput Screening (HTS) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Process, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 330 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

高通量篩檢(HTS) 市場預計將從 2024 年的 254 億美元成長到 2034 年的 478 億美元，複合年成長率約為 6%。高通量篩檢(HTS) 市場涵蓋用於快速測試大量化合物和生物分子的技術和調查方法。 HTS 透過快速辨識與特定生物路徑相關的活性化合物、抗體或基因，加速藥物發現進程。自動化、小型化和數據分析技術的進步推動了市場成長，這些進步提高了篩檢的效率和準確性。製藥和生物技術領域對創新藥物發現解決方案的需求不斷成長，推動了市場發展，而人工智慧的融合則為預測分析和決策增添了新的維度。

在製藥業對高效能藥物發現流程的需求推動下，高通量篩檢(HTS) 市場正快速發展。耗材領域在性能方面發揮主導作用，試劑和檢測試劑盒是 HTS 操作效率的關鍵。自動化液體處理系統和檢測儀器也至關重要，能夠提高通量和準確性。軟體和服務領域也呈現成長態勢，這得益於先進數據分析和機器學習演算法的整合，它們能夠解讀複雜的生物數據。基於細胞的檢測方法已成為性能最高的子領域，與傳統的生化檢測方法相比，能夠提供更生理相關的數據。然而，生化檢測方法由於其在早期篩檢階段的現有地位，仍佔據著重要地位。基於雲端的 HTS 平台應用日益廣泛，提供了擴充性和遠端資料存取功能。能夠滿足特定研究需求並最佳化資源分配的客製化 HTS 解決方案正逐漸獲得市場認可。對人工智慧驅動的 HTS 技術的投資不斷成長，正在提高篩檢效率和準確性，進一步推動市場成長。

市場區隔
類型 基於細胞的檢測、生化檢測
產品 設備、試劑和檢測試劑盒、耗材和配件
服務 合約研究服務、外包服務
科技 自動化、小型化和奈米技術
成分 軟體、硬體
應用 藥物發現、標靶辨識、篩檢、毒性評價
最終用戶 製藥和生物技術公司、學術和研究機構、受託研究機構
過程 篩檢，複篩檢
實施表格 本機部署、雲端部署
功能 資料管理和分析工具

高通量篩檢(HTS) 市場正經歷市場佔有率、定價策略和產品創新方面的動態變化。主要產業領導者致力於採用先進的 HTS 技術來提升藥物發現流程。價格競爭依然激烈，各公司都在努力平衡成本效益與技術進步。該市場的特點是擁有強大的新產品平臺，並強調自動化和人工智慧整合以提高營運效率。這催生了一個競爭激烈的環境，各公司正透過策略聯盟和收購來爭奪市場主導地位。 HTS 市場的競爭異常激烈，主要參與者不斷相互比較，以保持競爭優勢。監管影響發揮重要作用，尤其是在北美和歐洲等地區，這些地區有著嚴格的市場營運準則。各公司正透過投資合規和品質保證來應對這些法規。亞太地區的新興市場正變得至關重要，由於有利的監管環境和不斷成長的研發投資，這些市場提供了盈利的機會。在技​​術進步和對高效藥物發現解決方案日益成長的需求的驅動下，該市場擁有光明的前景。

主要趨勢和促進因素：

由於自動化和小型化技術的進步，高通量篩檢(HTS) 市場正經歷強勁成長。這些創新顯著提高了篩檢過程的效率和準確性，使研究人員能夠精確處理大量樣本。因此，製藥公司擴大採用 HTS 來加速藥物發現和開發。此外，人工智慧 (AI) 和機器學習與 HTS 的融合正在革新數據分析。這些技術能夠快速解讀複雜的資料集，最佳化先導化合物的篩選，並縮短新治療方法的上市時間。對個人化醫療的需求也在推動 HTS 的應用，有助於識別針對個別患者特徵的潛在治療標靶。此外，慢性病盛行率的上升也推動了對創新藥物發現方法的需求，進一步促進了 HTS 市場的發展。新興市場在醫療基礎設施不斷改善和研發投入日益增加的推動下，蘊藏著許多機會。投資先進 HTS 技術和策略合作的公司將能夠更好地掌握這些蓬勃發展的機會。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 基於細胞的檢測
    • 生化分析
  • 市場規模及預測：依產品分類
    • 裝置
    • 試劑和檢測試劑盒
    • 耗材和配件
  • 市場規模及預測：依服務分類
    • 合約研究服務
    • 外包服務
  • 市場規模及預測：依技術分類
    • 自動化
    • 縮減規模
    • 奈米科技
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
  • 市場規模及預測：依應用領域分類
    • 藥物發現
    • 目標識別
    • 篩檢
    • 毒性評價
  • 市場規模及預測：依最終用戶分類
    • 製藥和生物技術公司
    • 學術和研究機構
    • 合約研究機構
  • 市場規模及預測：依製程分類
    • 篩檢
    • 二次篩檢
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：依功能分類
    • 資料管理
    • 分析工具

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Charles River Laboratories
  • Perkin Elmer
  • Tecan Group
  • Molecular Devices
  • Bio Tek Instruments
  • Hamilton Company
  • BMG LABTECH
  • Analytik Jena
  • Aurora Biomed
  • Corning Incorporated
  • Greiner Bio-One
  • Brooks Life Sciences
  • Hudson Robotics
  • Cisbio Bioassays
  • Berthold Technologies
  • Axxam
  • Enzo Life Sciences
  • Genedata
  • Evotec
  • Bio-Rad Laboratories

第9章：關於我們

簡介目錄
Product Code: GIS20839

High-Throughput Screening (HTS) Market is anticipated to expand from $25.4 billion in 2024 to $47.8 billion by 2034, growing at a CAGR of approximately 6%. The High-Throughput Screening (HTS) Market encompasses technologies and methodologies for rapidly testing large volumes of chemical compounds or biological molecules. HTS accelerates drug discovery by enabling the swift identification of active compounds, antibodies, or genes pertinent to specific biological pathways. The market is propelled by advancements in automation, miniaturization, and data analytics, which enhance screening efficiency and accuracy. Increasing demand in pharmaceutical and biotechnology sectors for innovative drug development solutions fuels growth, while integration with artificial intelligence offers new dimensions in predictive analytics and decision-making.

The High-Throughput Screening (HTS) Market is advancing rapidly, propelled by the pharmaceutical industry's demand for efficient drug discovery processes. The consumables segment leads in performance, with reagents and assay kits being pivotal for streamlining HTS operations. Automated liquid handling systems and detection instruments are also critical, enhancing throughput and precision. The software and services segment follows closely, driven by the integration of advanced data analytics and machine learning algorithms to interpret complex biological data. Cell-based assays are emerging as the top-performing sub-segment, offering more physiologically relevant data compared to traditional biochemical assays. The biochemical assays sub-segment, however, remains significant due to its established role in initial screening phases. The adoption of cloud-based HTS platforms is increasing, providing scalability and remote access to data. Customized HTS solutions are gaining traction, addressing specific research needs and optimizing resource allocation. Growing investments in AI-driven HTS technologies further fuel market growth, enhancing screening efficiency and accuracy.

Market Segmentation
TypeCell-based Assays, Biochemical Assays
ProductInstruments, Reagents & Assay Kits, Consumables & Accessories
ServicesContract Research Services, Outsourcing Services
TechnologyAutomation, Miniaturization, Nanotechnology
ComponentSoftware, Hardware
ApplicationDrug Discovery, Target Identification, Primary Screening, Toxicology Assessment
End UserPharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations
ProcessPrimary Screening, Secondary Screening
DeploymentOn-premise, Cloud-based
FunctionalityData Management, Analysis Tools

The High-Throughput Screening (HTS) market is witnessing a dynamic shift in market share, pricing strategies, and product innovations. Key industry leaders are focusing on launching advanced HTS technologies to enhance drug discovery processes. Pricing remains competitive, with companies striving to balance cost efficiency and technological advancement. The market is characterized by a robust pipeline of new products, emphasizing automation and integration with artificial intelligence to streamline operations. This is fostering a competitive environment as companies vie for market dominance through strategic partnerships and acquisitions. Competition in the HTS market is intense, with major players continuously benchmarking against each other to maintain their competitive edge. Regulatory influences play a significant role, particularly in regions like North America and Europe where stringent guidelines dictate market operations. Companies are navigating these regulations by investing in compliance and quality assurance. Emerging markets in Asia-Pacific are becoming pivotal, offering lucrative opportunities due to favorable regulatory landscapes and increasing R&D investments. The market's future is promising, driven by technological advancements and growing demand for efficient drug discovery solutions.

Geographical Overview:

The High-Throughput Screening (HTS) market is witnessing substantial growth across various regions, each with unique opportunities. North America leads the market, propelled by robust pharmaceutical research and development activities. The presence of major biotechnology firms and advanced healthcare infrastructure further accelerates HTS adoption. Europe follows closely, with strong governmental support for drug discovery initiatives and the presence of established pharmaceutical companies. In the Asia Pacific region, the market is expanding rapidly due to increasing investments in healthcare infrastructure and growing biotechnology sectors. Countries like China and India are emerging as major growth pockets, driven by their large patient populations and rising healthcare expenditures. Latin America is also showing potential, with Brazil and Mexico investing in modernizing their pharmaceutical industries. The Middle East & Africa region is gradually recognizing the benefits of HTS, with countries like the UAE and South Africa focusing on enhancing their research capabilities to drive economic growth and innovation.

Global tariffs and geopolitical tensions are significantly influencing the High-Throughput Screening (HTS) market, with Japan, South Korea, China, and Taiwan at the forefront of these dynamics. Japan and South Korea are navigating trade barriers by enhancing their domestic R&D capabilities in biopharmaceuticals. China, facing technology export restrictions, is investing heavily in local HTS innovations. Taiwan, critical in semiconductor supply, is pivotal yet vulnerable to cross-strait tensions. Globally, the HTS market is buoyant, driven by innovations in drug discovery and personalized medicine. By 2035, the market is anticipated to witness robust growth, contingent on geopolitical stability and supply chain resilience. Middle East conflicts continue to impact global energy prices, indirectly affecting manufacturing and logistics costs across the HTS supply chain.

Key Trends and Drivers:

The High-Throughput Screening (HTS) market is experiencing robust growth fueled by advancements in automation and miniaturization technologies. These innovations are significantly enhancing the efficiency and accuracy of screening processes, enabling researchers to handle large volumes of samples with precision. As a result, pharmaceutical companies are increasingly adopting HTS to accelerate drug discovery and development. Moreover, the integration of artificial intelligence and machine learning in HTS is revolutionizing data analysis. These technologies facilitate the rapid interpretation of complex datasets, thereby optimizing lead identification and reducing time-to-market for new therapies. The demand for personalized medicine is also driving HTS adoption, as it aids in the identification of potential therapeutic targets tailored to individual patient profiles. Additionally, the rising prevalence of chronic diseases is propelling the need for innovative drug discovery methods, further boosting the HTS market. Opportunities abound in emerging markets, where healthcare infrastructure is expanding, and there is an increasing focus on research and development activities. Companies investing in advanced HTS technologies and strategic partnerships are well-positioned to capitalize on these burgeoning opportunities.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cell-based Assays
    • 4.1.2 Biochemical Assays
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Reagents & Assay Kits
    • 4.2.3 Consumables & Accessories
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Research Services
    • 4.3.2 Outsourcing Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Automation
    • 4.4.2 Miniaturization
    • 4.4.3 Nanotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Software
    • 4.5.2 Hardware
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Drug Discovery
    • 4.6.2 Target Identification
    • 4.6.3 Primary Screening
    • 4.6.4 Toxicology Assessment
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical & Biotechnology Companies
    • 4.7.2 Academic & Research Institutes
    • 4.7.3 Contract Research Organizations
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Primary Screening
    • 4.8.2 Secondary Screening
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-premise
    • 4.9.2 Cloud-based
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Data Management
    • 4.10.2 Analysis Tools

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Deployment
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Deployment
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Deployment
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Deployment
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Deployment
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Deployment
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Deployment
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Deployment
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Deployment
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Deployment
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Deployment
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Deployment
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Deployment
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Deployment
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Deployment
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Deployment
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Deployment
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Deployment
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Deployment
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Deployment
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Deployment
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Deployment
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Deployment
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Deployment
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Charles River Laboratories
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Perkin Elmer
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Tecan Group
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Molecular Devices
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bio Tek Instruments
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Hamilton Company
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 BMG LABTECH
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Analytik Jena
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Aurora Biomed
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Corning Incorporated
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Greiner Bio- One
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Brooks Life Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Hudson Robotics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cisbio Bioassays
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Berthold Technologies
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Axxam
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Enzo Life Sciences
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Genedata
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Evotec
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bio- Rad Laboratories
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us